Organoidsciences

At a glance

Organoidsciences filed 33 disclosures in the last 12 months, including 2 issuance and 1 5% holder. The most recent key filing was on Apr 30: Issuing 255,009 sh of new shares, equal to 3.9% of existing shares.

Revenue for 2025 was ₩2.4B, up 23.2% on 2024. It made an operating loss of ₩16.2B. Debt was 50% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩741.6M and operating loss of ₩8.6B.

The 2025 annual report lists 89 employees with an average tenure of 2.8 years and average pay of ₩53.9M, #1509 of 2,191 listed companies by average pay. Its 11 directors and auditors were paid ₩68.6M each on average. It paid no cash dividend for 2025. 유종만 and related parties held 27.36% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 30.63% on Apr 6.

From the 2025 annual report

Staff: 89 (40 men, 49 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩4.2B. Directors and auditors: 11, paid ₩754.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

유종만 holds 25.38%; with 2 related parties the group holds 27.36% of common shares at year end (from 34.16% at the start of the year).

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports